Floatz logo

FILGRASTIM

Dyskeratosis Congenita

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkinsprotein_peptidePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Dyskeratosis Congenita cohort.

Asset / SponsorPhaseRating
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
Evomela
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
TACROLIMUS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Masonic Cancer Center, University of Minnesota
Phase 2CCC
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2CCC

View all 11 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →